María Natalia Gandur Quiroga: New insights on immunotherapy rechallenge in mRCC
María Natalia Gandur Quiroga shared on X:
“New insights on immunotherapy rechallenge in mRCC!
Key takeaways:
– CONTACT-03 trial: Negative results for combining cabozantinib with atezolizumab post-ICI, raising questions on ICI rechallenge strategies.
– TiNivo-2 trial: Awaiting results on PD-1 inhibitor rechallenge in various post-ICI settings.
– Molecular insights: Identifying immune/proliferative and angiogenic clusters for tailored ICI and VEGF therapies.
– Ongoing research: Exploring durable responses and optimal timing for ICI rechallenges.
Speakers: Nazli Dizman, Marc Machaalani, Emre Yekedüz, and Toni Choueiri.”
Proceed to the article.
Source: María Natalia Gandur Quiroga/X
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023